Lonnie McMillian

Serina Therapeutics, Inc. is a pharmaceutical company, which engages in the development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley in 2006 and is headquartered in Huntsville, AL.

ADTRAN, Inc. engages in the provision of networking and communications platforms and services focused on the broadband access market. It operates through the Network Solutions and Services and Support business segment. The Network Solutions segment includes hardware products and next-generation virtualized solutions used in service provider or business networks, as well as prior-generation products. The Services and Support segment offers ProCloud managed services, network installation, engineering and maintenance services, and fee-based technical support and equipment repair/replacement plans. The company was founded by Mark C. Smith in November 1985 and is headquartered in Huntsville, AL.

The HudsonAlpha Institute for Biotechnology is a non-profit organization. It focuses on conducting genomics-based research to improve human health and well being; implementing genomic medicine, sparking economic development; and providing educational outreach to nurture the next generation of biotech researchers and entrepreneurs, as well as to create a biotech literate public. The company was founded by James R. Hudson, Jr. and Lonnie S. McMillian in 2008 and is headquartered in Huntsville, AL.

Systems Engineering Laboratory Co., Ltd. is engaged in software development, maintenance, and systems management services. The company is also involved in information equipment and software distribution. Systems Engineering Laboratory was established in 1979 and is based in Tokyo, Japan.

Motorola, Inc. provides seamless mobility products and solutions across broadband, embedded systems and wireless networks. Motorola is engaged in providing technologies, products and services for mobile phones. Its portfolio includes wireless handsets, wireless accessories, digital entertainment devices, wireless access systems, voice and data communications systems, and enterprise mobility products. The company operates through three business segments, including Mobile Devices Segment, Home and Networks Mobility Segment and Enterprise Mobility Solutions Segment. The Mobile Devices segment designs, manufactures, sells and services wireless handsets with integrated software and accessory products, and licenses intellectual property. The Home and Networks Mobility segment designs, manufactures, sells, installs and services: (i) digital video, Internet Protocol video and broadcast network interactive set-tops, end-to-end video delivery systems, broadband access infrastructure platforms, and associated data and voice customer premise equipment to cable television and telecom service providers, and (ii) wireless access systems, including cellular infrastructure systems and wireless broadband systems, to wireless service providers. The Enterprise Mobility Solutions segment designs, manufactures, sells, installs and services analog and digital two-way radio, voice and data communications products and systems for private networks, wireless broadband systems and end-to-end enterprise mobility solutions to government and public safety agencies, as well as retail, energy and utilities, transportation, manufacturing, healthcare and other commercial customers. Motorola was founded on September 25, 1928 and is headquartered in Schaumburg, IL

Egen, Inc. operates as a clinical stage biopharmaceutical company which develops novel proprietary nanoparticle delivery technology for therapeutic use. Egen's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas and TheraSilence platforms to the treatment of human disease. Egen's lead candidate, EGEN-001, is in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer. In addition, Egen is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies. It is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications. Egen offers cutting-edge research services relating to non-viral polymeric gene carrier systems, and other approaches for the delivery of nucleic acid and anti-cancer drugs. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking. Egen was founded in 2002 by Sung Wan Kim and is headquartered in Huntsville, AL.